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Abstract 
Purpose 
To determine the medium-term outcomes for patients with advanced glaucoma 
undergoing viscocanalostomy. 
 
Methods 
All patients with advanced glaucoma (Mean Deviation -12.00 dB or above) and patients 
with poor visual acuity secondary to advanced glaucoma which precluded formal 
visual-field assessment undergoing viscocanalostomy (VC) and phaco-
viscocanalostomy between 2010 and 2014 under the care of a single surgical team were 
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included. Intraocular pressure (IOP), visual acuity and visual field outcomes were 
assessed from data prospectively collected into a surgical outcome database. Success 
was defined at two IOP cut-off points: IOP ≤ 21mmHg and ≤ 16 mmHg with (qualified) 
or without (complete) medications.  
 
Results 
135 patients were included. Mean IOP changed from 23.6 ± 6.4 mmHg pre-operatively 
to 15.3, 15.8 and 14.8 mmHg between 1 and 3 years, a change of 35%, 33.5% and 39% 
respectively. Qualified success for an IOP ≤ 21mmHg was achieved in 95.66% at year 
1, 90.6% at year 2 and 80% at year 3. Qualified success for an IOP ≤ 16 mmHg was 
achieved in 66.6% at year 1, 66.05% at year 2 and 60% at year 3. The cumulative 
probability for achieving an IOP ≤ 21mmHg with or without drops was 86.1, 81.4 and 
81.4% at 12, 24 and 36 months. During the follow up period 11 patients (8%) failed to 
achieve adequate IOP control and needed further surgical intervention. Eleven (8.1%) 
patients needed an intervention (Yag goniopuncture) following viscocanalostomy. Four 
patients (2.9%) had some post-operative complication, which resolved within two 
weeks following surgery. Nine patients (6.7%) lost more than 2 Snellen lines. There 
was no significant change in the MD across time points. 
 
Conclusion  
Viscocanalostomy is a safe and effective method of controlling IOP in the medium-
term in patients with advanced glaucoma. 
 
Key words: Viscocanalostomy, advanced glaucoma, non-penetrating glaucoma 
surgery, glaucoma 
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Introduction 
Patients most at risk of blindness during their lifetime, due to glaucoma, are those who 
present with advanced disease. Saunders et al [1] reported that almost 60% of patients 
progressing to statutory blindness had one eye with an MD worse than −14 dB at 
baseline. 10% to 39% of glaucoma patients present with advanced disease in at least 
one eye in the UK [2-4]. In a questionnaire to all the UK consultant ophthalmologists 
the consensus opinion for both glaucoma specialists and non-glaucoma specialists was 
to start with primary medical therapy, most commonly citing surgical risk as the 
primary reason (23% and 22% respectively) [5].  
National Institute for Health and Clinical Excellence (NICE) guidelines suggested 
different management approaches for patients presenting with early and advanced 
disease where the latter should be offered primary surgery [6]. However, there is limited 
evidence supporting this recommendation and the type of surgery to be offered.  
Stead and King [7] have reported medium-term results for trabeculectomy combined 
with Mitomycin-C (MMC) in patients with advanced glaucoma (MD ≤ 20dB). 
Although trabeculectomy was successful at controlling IOP in this group, a quarter of 
patients experienced a significant reduction in acuity. The only pre-operative 
determinant for a significant reduction in VA was the pre-operative MD.  
The treatment for advanced glaucoma study (TAGS) will report the outcomes of 
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primary trabeculectomy compared with medical management for advanced glaucoma 
[8]. Non-penetrating glaucoma surgery (NPGS) has been shown to provide comparable 
long-term success rates to trabeculectomy, with reduced postoperative complications 
[9-11] but there is limited information on its success in patients with advanced 
glaucoma. 
In this study, we assessed the outcomes of viscocanalostomy in patients with advanced 
glaucoma to document success in terms of IOP and visual acuity. In addition, we 
quantified the postoperative interventions undertaken to achieve these outcomes. 
 
Methods 
Advanced glaucoma was classified as MD between -12.00 to -20.00 dB and severe 
glaucoma MD  -20.01dB or worse [12]. 
All patients with advanced glaucoma and patients with poor visual acuity secondary to 
advanced glaucoma which precluded formal visual-field assessment undergoing 
viscocanalostomy (VC) and phaco-viscocanalostomy between 2010 and 2014 under the 
care of a single surgical team were included.  
The technique involved superior corneal traction with 7-0 vicryl. The conjunctiva and 
Tenon’s capsule were then opened in the upper fornix to expose the sclera. Careful 
haemostasis using wet field cautery was performed. A two-third scleral thickness 
limbus based scleral flap measuring 5x5 mm was dissected and advanced 1 mm into 
clear cornea. A 4x4 mm deep scleral flap was then dissected reaching Schlemm’s canal, 
which was de-roofed and extended into corneal stroma to the level of Descemet’s 
membrane to create the trabeculo-Descemet’s membrane (TDM). High viscosity 
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hyaluronic acid (Viscoat TM) was injected into the two surgically created ostia of 
Schlemm’s canal, aiming at dilating both the ostia and the canal and was also placed in 
the scleral bed. The deep flap was excised close to the TDW. The superficial scleral 
flap and conjunctiva were closed with 10-0 vicryl sutures. No antimetabolite was used. 
There were no specific exclusion criteria. Data on all patients were included until the 
last recorded appointment, which was considered the end of their follow-up. Post-
operatively patients were followed up day 1, week 1, month 3, month 6, and then every 
6 months. Minimum follow up was 1 year. An intervention was defined as any 
procedure or process undertaken after viscocanalostomy aimed at enhancing the 
success of the surgical outcome. This was Nd:YAG laser goniopuncture. 
Primary outcomes were changes in IOP and visual field (MD). These were assessed 
from data prospectively collected into a surgical outcome database. Secondary 
outcomes were change in visual acuity, post-operative complications and interventions 
and number of glaucoma drops used. 
 Subgroup analysis was performed to look at confounding factors such as age, race, 
combined cataract surgery and previous glaucoma surgery or laser. Differences in 
outcomes between primary open angle glaucoma (POAG) and secondary glaucoma 
were also examined. 
With regards to statistical analysis normality of intraocular pressure (IOP), number of 
drops (Drops) and visual field mean deviation (MD) data was examined using the 
Kolmogorov-Smirnov test.  Further, pre-operative MD scores were divided into two 
groups; MD between -12 and -20 dB, and MD -20.01 dB and worse, and normality was 
also examined. Consequently, a linear mixed model was used to examine for 
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differences in IOP and MD between pre-operative (pre-op) and year one (Y1), year two 
(Y2), year three (Y3) post-operatively and to compare the two MD groups at these time 
points. Drops were examined with Friedman’s test and if a difference was found, 
pairwise comparisons were conducted using Wilcoxon test. Associations between 
presenting IOP, cataract surgery post-viscocanalostomy and combined surgery were 
examined with point biserial correlation. For all statistical analysis, IBM SPSS v22 
(SPSS, Chicago, Illinois) was used.  
 
Success definition: 
Complete surgical success was defined as IOP≤21 mmHg with no additional 
medication and qualified surgical success, an IOP≤21 mmHg with additional glaucoma 
medication. Failure was defined as IOP >21 mmHg on 2 consecutive visits, IOP ≤ 5 
mmHg on 2 consecutive study visits after 3 months, reoperation for glaucoma or loss 
of light perception. Success was also defined at two IOP cut-off points (IOP≤21 mm 
Hg and IOP≤16 mm Hg). Visual acuity was measured on a Snellen chart, and a 
reduction of two or more lines was considered clinically significant.  
 
Results 
In total 135 eyes of 133 patients were identified for the study. The patients’ 
demographics for all variables over time can be seen in Table 1. Sixty three (46.7%) 
patients had combined viscocanalostomy with cataract surgery. The vast majority of 
eyes (132) were on topical drops preoperatively. IOP at diagnosis was not known in 55 
patients, as these were referred from other units, and this information was not provided. 
Twenty-five patients had previous intervention for glaucoma including trabeculectomy, 
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cyclodiode, Argon laser trabeculoplasty (ALT) and Selective laser trabeculoplasty 
(SLT) (Table 1). 
 
IOP outcome 
IOP was significantly lower at all examined time points (Y1: by 35.0%; Y2: by 33.5%; 
Y3: by 39.2% p < 0.001 at all time points) compared to the pre-op value. Glaucoma 
drops were significantly different across time points (p = 0.001) with a significantly 
lower median at all examined time points compared to pre-op drops. Visual field MD 
was not significantly different across time points (p = 0.289). When comparing IOP, 
drops and MD scores between the two MD groups, no significant interaction was seen 
between groups and time points for IOP (p = 0.999), Drops (p = 0.384) or MD (p = 
0.061). Descriptive statistics of all of the above can be seen in Table 2, while Figure 1 
displays IOP and Drops data plotted over the time points. 
With regards to qualified and complete success (Table 3), at year 1 qualified success 
was noted in 95.66% patients (for IOP≤21 mmHg) and 66.6% patients (for IOP≤16). 
Complete success was noted in 52.5% and 44.8% respectively. At year 2, qualified 
success was noted in 90.6% patients (for IOP≤21 mmHg) and 66.05% patients (for 
IOP≤16). Complete success was noted in 48.6% and 37.6% respectively. At year 3, 
qualified success was noted in 80% patients (for IOP≤21 mmHg) and 60% patients (for 
IOP≤16). Complete success was noted in 30.6% patients in both groups.  
During the follow up period 11 patients (8%) failed to reach any of the above success 
criteria and needed further surgical intervention. Four patients failed in year 1, another 
four patients in year 2 and another three patients in year 3 (Table 4). Of these, 4 had 
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uveitic glaucoma, 2 were pseudoexfoliative glaucoma (PXFG) and five were Primary 
Open Angle Glaucoma (POAG). 
Kaplan-Meier survival curves were significantly different between complete and 
qualified success with IOP≤21 (p = 0.001, Figure 2) but not between different glaucoma 
types for either complete (p = 0.912) or qualified success (p = 0.541). Kaplan-Meier 
survival curves were not significantly different between MD groups for complete (p = 
0.512) and qualified (p = 0.079) success. 
 
Visual Acuity outcome 
Visual acuity was stable for the vast majority of patients (126 patients, 93.3%). Nine 
patients lost more than 2 Snellen Lines.  The reason for reduced vision in 7 patients was 
glaucoma and high myopia and proliferative diabetic retinopathy in the other 2 patients. 
Majority of these patients (8 out of 9) had MD worse than -20dB. In 2 patients with 
MD < -20 dB visual acuity dropped significantly from 6/36 at pre-op to hand movement 
and perception of light in the early post-operative period (presumed wipe out).  
 
Visual field changes 
Prior to surgery 20 patients were unable to perform a reliable visual field test (24-2 
Humphrey visual field). During the follow up period the number of patients that were 
able to perform a reliable visual field test gradually decreased. A total number of 52 
patients completed a reliable field test from 115 at pre-op. In those patients mean 
deviation (MD) was not significantly different across time points (p = 0.105) compared 
to pre-op.  
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Confounding factors 
Twenty-five patients had previous surgery. Presenting IOP, age, glaucoma type, 
glaucoma duration and having previous surgery did not comprise a sufficiently good 
model that could predict the intervention (Yag GP, p = 0.128) or intra- and post-
operative complications following surgery (p = 0.175). The patient group that had 
combined surgery and the patient group that did not, were not significantly different in 
outcome (p = 0.313). All descriptive statistics of the above variables can be found in 
Table 1. 
 
Cataract surgery 
Of the 59 patients who underwent viscocanalostomy alone and were phakic at the time 
of surgery, 3 patients (5%) underwent cataract surgery following viscocanalostomy by 
their final follow-up. Twenty-three (17%) were pseudophakes pre-viscocanalostomy. 
 
Complications 
Four patients (2.9%) had some post-operative complication during the follow up period, 
which resolved within two weeks following viscocanalostomy and did not cause any 
visual loss (Table 5). 
 
Post-operative intervention 
Eleven (8.1%) patients needed an intervention (Yag GP) following their operation. The 
time frame for the intervention varied between 2 months to 18 months.   
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Discussion 
We report our results with un-augmented VC in a cohort of patients with advanced 
glaucoma. VC was able to achieve an IOP ≤ 21mmHg in 80 to 95% patients with a 35-
39% drop in IOP from baseline with a good safety profile. To our knowledge, our study 
provides the largest number of eyes with the longest follow up yet reported for VC in 
patients with advanced glaucoma.  
There is limited evidence for the outcomes of glaucoma surgery for advanced glaucoma 
and no recent studies reporting the outcomes of NPGS for this cohort of patients. Ates 
et al [13] reported their experience of deep sclerectomy in 54 eyes with advanced 
glaucoma in 1999. 2 eyes out of 54 (3.8%) had IOP greater than 18 mmHg following 
non-penetrating deep sclerectomy and collagen implant. In our cohort, IOP reduction 
was maintained significantly below pre-operation levels up to 3 years after surgery. We 
have previously reported qualified (87.5-90.2%) and complete success (78– 90%) rates 
in a cohort of patients with POAG [10]. Shaarawy et al [11] have previously reported 
a 90% qualified and 60% complete success rate at 5 years with VC. It is likely that 
Schlemm’s canal sclerosis and collapse with advanced disease is the most likely 
explanation for the lower complete success rates for VC in the present study. We have 
previously augmented VC with MMC in high-risk eyes [9] but did not find a difference 
in outcome when compared to un-augmented VC [9, 10], which suggests a possible 
bleb-independent mechanism for the success of VC. 
Trabeculectomy is still considered the gold standard and achieves better control of IOP 
than viscocanalostomy [14]. The benefits of NPGS however, are potential gains for the 
patient in terms of their quality of life and reduced likelihood for post-operative 
interventions and sight-threatening complications [14]. Kirwan et al [15] in a recent 
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multicenter analysis of current trabeculectomy practice reported the requirement for 
frequent post-operative interventions in the majority of patients. They concluded that 
intensive proactive post-operative care is required after trabeculectomy and completion 
of trabeculectomy surgery is just the beginning of a process that takes several months 
to complete.  
There are no like for like trials and limited published data to compare our results to 
those for trabeculectomy or NPGS in a similar patient cohort. Stead and King’s [7] 
results for trabeculectomy augmented with MMC in advanced glaucoma fare better in 
terms of IOP control compared to our group. However, with regards to post-operative 
interventions, 79.8% patients had some form of bleb manipulation [7] compared to only 
8.1% in our study that had Yag goniopuncture.  
Reduced visual acuity is well recognised complication of glaucoma surgery and might 
be due to glaucoma progression, comorbidity or the procedure itself. Kirwan et al [15] 
reported the outcomes of 428 trabeculectomies. 15% had lost > 1 Snellen line at 1 year 
and 6% had lost >2 Snellen lines by 2 years post trabeculectomy (13% with advanced 
visual field loss). 27% of patients in Stead and King’s study experienced a loss of two 
or more lines of Snellen acuity [7]. 9 patients (6.7%) in our study experienced a loss of 
>2 Snellen lines. Eight out of these 9 patients had a MD worse than 20 dB. The drop in 
vision was attributed to glaucomatous progression in 7 eyes (5.2%); 2 (1.5%) of which 
were presumed to be a wipeout. The risk of loss of central vision in patients with 
advanced visual field loss ranges from rare to as high as 14% [16, 17]. This may be 
attributable to readily identifiable complications including cataract, cystoid macular 
edema, suprachoroidal and vitreous haemorrhage, endopthalmitis and uveitis or be 
unexplained (wipe-out). The exact mechanism of the “wipe-out” phenomenon remains 
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elusive, but it has been suggested that it may be associated with the occurrence of 
sudden intra-operative hypotony resulting in optic nerve hemorrhage and decreased 
perfusion pressure to an already compromised nerve blood supply [18]. The lower rates 
of drop in vision in the present study reflect the benefit of avoiding sudden 
decompression of the eye in patients with end-stage glaucoma with viscocanalostomy. 
Cataract formation is a reported complication after trabeculectomy and can be in the 
order of 78% [19]. More recent data suggest this to be in the order of 30% [15]. King 
et al [7] reported a 63% incidence of cataract formation post trabeculectomy requiring 
cataract surgery in 27% cases. Only 3 patients (5%) in our group required cataract 
surgery in the study period. Cataract surgery can decrease the success of a 
trabeculectomy with an increased likelihood of post-operative interventions and 
requirement for glaucoma medication in 30-39% cases [20, 21]. These risks are avoided 
with VC due to its bleb-independent mechanism of action.  
NICE recommends primary surgery should be offered to patients presenting with 
advanced loss [6]. Stead and King recommend this to be trabeculectomy augmented 
with MMC [7]. The use of antimetabolites is a recognized risk factor for bleb-related 
infection and endophthalmitis [22] which is more pronounced in this group of patients 
and reflects the opinion of UK Consultants’ for not advocating primary surgery for this 
group [2]. Avoidance of antimetabolite use and bleb–related complications with 
viscocanalostomy is an important consideration in this group of patients and even more 
so in patients with thin conjunctiva, childbearing age and pregnant patients. A major 
advantage of VC compared with trabeculectomy is retention of the TDW which appears 
to serve as a barrier to infection [22] and allows titrated aqueous flow, thus avoiding 
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hypotony and its complications such as shallow and flat anterior chamber, choroidal 
detachments and suprachoroidal haemorrhages.  
Non-penetrating filtering surgical techniques have greater safety with a lower risk of 
complications when compared to trabeculectomy [22-25]. The UK national 
trabeculectomy surgery survey [26], which reported outcomes of more than 1200 
trabeculectomies, reported early complications in 578 cases (46.6%) and late 
complications in 512 cases (42.3%). Kirwan et al reported an incidence of 14% bleb 
leaks, 7.2% late onset hypotony and 0.75% endophthalmitis with trabeculectomy [15]. 
A Cochrane review [14] reported relatively fewer complications with non-penetrating 
glaucoma surgery (17%) compared to trabeculectomy (65%). In our study only 4 
patients (2.9%) had some post-operative complication, which resolved within two 
weeks following viscocanalostomy and did not result in any long-term complications. 
Our study showed that mean deviation was not significantly different across time points 
(p = 0.105) compared to pre-op. It remained stable around 19dB. However, the number 
of patients completing the field test declined slightly year on year which may be 
expected with time [1], with 45.2% of patients finally having a reliable field test. Our 
results are comparable to previous reports where only 39% of patients with advanced 
glaucoma were able to complete a reliable field test 1-year post-trabeculectomy [7, 27].  
Eleven eyes failed and required further surgery. Of these 4 had uveitic glaucoma (3 
Fuchs’ heterochromic cyclitis (FHC)) and 2 pseudoexfoliative glaucoma (PXFG) both 
known to have an aggressive course and a poor surgical outcome [28]. We have 
previously reported good outcomes for NPGS in uveitic glaucoma [10]. In this study 8 
pts had uveitic glaucoma of which 3 had FHC. All patients with FHC failed. The failure 
of VC in FHC could be related to the increased likelihood of subclinical 
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neovascularisation and Schlemm’s canal sclerosis in these patients [29].  
Limitations of this study include the loss of numbers, particularly those able to complete 
a reliable visual-field test during the follow-up period. However, to our knowledge this 
is the first study to report the effectiveness of un-augmented viscocanalostomy in a 
cohort of patients with advanced glaucoma. IOP remained controlled over a period of 
up to 3 years, albeit with the requirement of increasing medications with time and visual 
acuity remained stable in the majority of patients. Viscocanalaostomy had similar 
qualified success rate to MMC trabeculectomy with a good safety profile, avoidance of 
MMC and its attendant complications and minimal post-operative interventions. The 
benefits also transpose to the wider context of economic and quality of life benefits to 
be achieved with non-penetrating glaucoma surgery [30].  NICE recommends primary 
surgery in this group of patients [6]. TAGS will address the outcomes of primary 
trabeculectomy for advanced glaucoma [8]. Our study supports the extension of the trial 
to include the use of primary viscocanalostomy for advanced glaucoma. 
 
 
 
 
 
 
 
References 
1. Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP (2014) Examining 
visual field loss in patients in glaucoma clinics during their predicted remaining 
lifetime. Invest Ophthalmol Vis Sci 55:102-9  
 15 
2. Ng WS, Agarwal PK, Sidiki S McKay L, Townend J, Azuara-Blanco A (2010) The 
effect of socio-economic deprivation on severity of glaucoma at presentation. Br J 
Ophthalmol 94:85-7 
3. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, 
Butterfield LC, Gray DT (1998) The probability of blindness from open-angle 
glaucoma. Ophthalmology 105:2099-104  
4. Coffey M, Reidy A, Wormald R, Xian WX, Wright L, Courtney P (1993) Prevalence 
of glaucoma in the west of Ireland. Br J Ophthalmol 77:17- 21 
5. King AJ, Stead RE, Rotchford AP (2011) Treating patients presenting with advanced 
glaucoma should we reconsider current practice? Attitudes of consultant 
ophthalmologists in the UK to initial management of glaucoma patients presenting with 
severe visual field loss: a national survey. Clinical and Experimental Ophthalmology 
39:858-64 
6. NICE Guideline NG81 (2017) Glaucoma: diagnosis and management. 
https://www.nice.org.uk/guidance/ng81. Accessed 14 March 2018 
7. King AJ, Stead RE (2011) Outcome of trabeculectomy with mitomycin C in patients 
with advanced glaucoma. Br J Ophthalmol 95:960-5 
8. King AJ, Fernie G, Azuara-Blanco A, Burr JM, Garway-Heath T, Sparrow JM, Vale 
L, Hudson J, MacLennan G, McDonald A, Barton K, Norrie J (2017) Treatment of 
Advanced Glaucoma Study: a multicentre randomised controlled trial comparing 
primary medical treatment with primary trabeculectomy for people with newly 
diagnosed advanced glaucoma-study protocol. Br J Ophthalmol Oct 26 pii: 
bjophthalmol-2017-310902. doi: 10.1136/bjophthalmol-2017-310902. [Epub ahead of 
print]  
9. Choudhary A, Wishart PK (2007)  Non-penetrating glaucoma surgery augmented 
 16 
with mitomycin C or 5-fluorouracil in eyes at high risk of failure of filtration surgery: 
long-term results. Clinical and Experimental Ophthalmology 35:340-47 
10. Wishart PK, Wishart MS, Choudhary A, Grierson I (2008) Long-term results of 
viscocanalostomy in pseudoexfoliative and primary open angle glaucoma. Clin Exp 
Ophthalmol 36:148-55 
11. Shaarawy T, Nguyen C, Schnyder C, Mermoud A (2003) Five year results of 
viscocanalostomy. Br J Ophthalmol 87:441-5 
12. Mills RP, Budenz DL, Lee PP Noecker RJ, Walt JG, Siegartel LR, Evans SJ, Doyle 
JJ (2006) Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. 
Am J Ophthalmol 141: 24-30 
13. Ates H, Andac K, Uretmen O (1999) Non-penetrating deep sclerectomy and 
collagen implant surgery in glaucoma patients with advanced field loss. Int Ophthalmol 
123:123-8 
14. Eldaly MA, Bunce C, Elsheikha OZ, Wormald R. (2014) Non-penetrating filtration 
surgery versus trabeculectomy for open-angle glaucoma. Cochrane Database Syst Rev. 
Feb 15:(2) 
15. Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway DC, King AJ, McNaught 
AI, Agrawal P; Trabeculectomy Outcomes Group Audit Study Group (2013) 
Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology. 120:2532-
9 
16. Topouzis F, Tranos P, Koskosas A, Pappas T, Anastasopoulos E, Dimitrakos S, 
Wilson MR (2005) Risk of sudden visual loss following filtration surgery in end-stage 
glaucoma. Am J Ophthalmol 140:661-66 
17. Kolker AE (1977) Visual prognosis in advanced glaucoma: a comparison of 
medical and surgical therapy for retention of vision in 101 eyes with advanced 
 17 
glaucoma. Trans Am Ophthalmol Soc 75:539-55 
18. Lichter PR (1974) Risks of sudden visual loss after glaucoma surgery. Am J 
Ophthalmol 78:1009-13 
19. AGIS (Advanced Glaucoma Intervention Study) Investigators. The Advanced 
Glaucoma Intervention Study: 8 (2001) Risk of cataract formation after 
trabeculectomy. Arch Ophthalmol 119:1771-79 
20.  Husain R, Liang S, Foster PJ, Gazzard G, Bunce C, Chew PT, Oen FT, Khaw 
PT, Seah SK, Aung T (2012) Cataract surgery after trabeculectomy: 
the effect on trabeculectomy function. Arch Ophthalmol 130:165-70 
21. Longo A, Uva MG, Reibaldi A, Avitabile T, Reibaldi M (2015) Long-
term effect of phacoemulsification on trabeculectomy function. Eye 29:1347-52  
22. Ang GS, Varga Z, Shaarawy T (2010) Postoperative infection in penetrating versus 
non-penetrating glaucoma surgery. Br J Ophthalmol 94:1571-76 
23. Mendrinos E, Mermoud A, Shaarawy T (2008) Nonpenetrating glaucoma surgery. 
Surv Ophthalmol 53: 592–630 
24. Ahmed II, Shaarawy T (2004) Viscocanalostomy versus trabeculectomy. 
Ophthalmology 111:1066-7 
25. Tan JC, Hitchings RA (2001) Non-penetrating glaucoma surgery: the state of play. 
Br J Ophthalmol 85:234-7 
26. Edmunds B, Thompson JR, Salmon JF, Wormald RP (2002) The National Survey 
of Trabeculectomy. III. Early and late complications. Eye 16:297-303 
27. Law SK, Nguyen AM, Coleman AL (2007) Severe loss of central vision in patients 
with advanced glaucoma undergoing trabeculectomy. Arch Ophthalmol 125:1044-50 
28. Jones NP (1993) Fuchs’ Heterochromic Uveitis: An Update. Survey of 
Ophthalmology 34:253-72 
 18 
29. Benedikt O, Roll P, Zirm M (1978) The glaucoma in heterochromic cyclitis of 
Fuchs. Gonioscopic studies and electron microscopic investigations of the trabecular 
meshwork. Klin Monatsbl Augenheilkd 173:523-33 
30. Traverso CE, Walt JG, Kelly SP et al (2005) Direct costs of glaucoma and severity 
of the disease: a multinational long term study of resource utilisation in Europe. Br J 
Ophthalmol 89:1245-9 
 
 
 
 19 
TABLES 
 
Table 1. Patients’ demographics. Patient numbers (and as percentage of whole sample), mean ± SD or median and range (minimum to maximum 
values), as appropriate, are presented for each variable.    
 
 N (%) Mean SD Median Range 
Age (years) 135 (100) 69.8 13.9 73 25 to 92 
Duration of glaucoma (years) 101 (74.8) 10.8 7.1 10 1 to 30 
Presenting intraocular pressure (mm Hg) 78 (57.8) 32.7 12.0 29 17 to 64 
Preoperative intraocular pressure (mm Hg) 134 (100) 23.5 6.0 22 14 to 44 
Preoperative visual acuity 111 (82.2)   6/6-6/9 6/6-6/9 to hand movement 
Preoperative drops (number) 135 (100) 3.1 1.1 3 0 to 5 
Preoperative MD (dB) 115 (85.2) -19.6 5.5 -19.4 -12 to -32.7 
Previous procedures      
  None 110 (81.4)     
  Trabeculectomy 11 (8.1)     
  Retinal detachment  surgery 7 (5.2)     
  SLT, ALT 4 (3.0)     
  Cyclodiode 3 (2.2)     
Glaucoma type      
  Primary open-angle glaucoma 92 (68.1)     
  Chronic angle closure glaucoma 11 (8.1)     
  Pseudoexfoliation 10 (7.4)     
  Uveitic 8 (5.9)     
  Pigment dispersion syndrome 6 (4.4)     
  Normal tension glaucoma 5 (3.7)     
  Fuch’s heterochromic cyclitis 3 (2.2)     
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Table 2. Descriptive statistics of IOP, Drops and MD at all time points including number of patients per year. IOP and MD data is presented as 
mean ± SD, while Drops data as median and range. *denotes significant difference with Pre-op.    
 
 Pre-op (135) Y1 (135) Y2 (109) Y3 (75) 
IOP (mm Hg) 23.6 ± 6.4  15.3 ± 3.2* 15.8 ± 4.1* 14.8 ± 3.4* 
  for MD between -12.01 and -20.00 dB 22.1 ± 5.2 15.3 ± 3.1 15.9 ± 3.3 15.0 ± 2.7 
  for MD -20.01 dB and worse 23.9 ± 6.5 15.5 ± 3.6 15.2 ± 3.1 14.8 ± 3.8 
Drops (number of) 3, 0 – 5  0, 0 – 3* 1, 0 – 4* 1, 0 - 4* 
Mean Deviation (dB) -19.6 ± 5.5  -18.8 ± 5.6  -18.0 ± 10.5  -19.8 ± 4.4 
IOP, intraocular pressure; Drops, number of medications; MD, mean deviation; M6, month six post-operation; Y1, year one post-operation;  Y2, 
year two post-operation; Y3, year three post-operation;  
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Table 3. Number and percentage of patients achieving IOP≤16 mmHg with no medication, IOP≤16 mmHg with additional medication, IOP≤21 
mmHg with no medication, and IOP≤21 mmHg with additional medication for all time points.    
 
 Y1 Y2 Y3 
IOP≤16 mmHg with no medication 60/135 (44.8%) 41/109 (37.6%) 23/75 (30.6%) 
IOP≤16 mmHg with additional medication 90/135(66.6%) 72/109 (66.05%) 45/75 (60.0%) 
IOP≤21 mmHg with no medication 71/135 (52.5%) 53/109 48.6% 23/75 (30.6%) 
IOP≤21 mmHg with additional medication 129/135(95.66%) 96/109 (90.6%) 60/75 (80%)  
IOP, intraocular pressure; Y1, year one post-operation;  Y2, year two post-operation 1; Y3, year three post-operation.  
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Table 4. Descriptives of failures.  
 
No Type of 
glaucoma 
Previous surgery/ 
laser 
Pre-op 
IOP(mmHg) 
Pre-op 
MD(dB) 
Pre-op 
BCVA 
Pre-op drops 
(No) 
BCVA at 
final follow 
up 
MD (dB) at 
final follow up 
Time of failure 
post-op 
(months) 
1 FHC* nil 20 U/C* 6/60 3 6/60 U/C* 24 
2 FHC* nil 32 -18.59 6/12 3 6/18 -21.54 36 
3 POAG* nil 28 -25.7 6/6 1 6/9 -29.23 36 
4 PXF* nil 39 -27.48 6/36 5 6/36 U/C* 24 
5 POAG Previous VS* 30 -12.87 6/6 4 6/9 -14.85 24 
6 FHC* nil 28 -23.92 6/12 4 6/18 -25.48 24 
7 POAG nil 24 -21.73 6/6 4 6/9 -22.68 12 
8 POAG nil 24 U/C* 6/60 4 6/60 U/C* 24 
9 Uveitic 
glaucoma 
cyclodiode 28 -14.73 6/24 4 6/36 -16.73 24 
10 POAG nil 25 -16.73 6/6 4 6/6 -17.75 12 
11 PXF trabeculectomy 16 -21.07 6/12 4 6/12 -22.78 24 
*U/C: Unable to perform reliable fields 
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Table 5. Intra- and post-operative complications. 
 
Complication type No of patients  
Intra-op TDW* perforation 17/135 
Wound conjunctival leak treated with  
bandage contact lens 
2/135 
Scleral flap leak repaired with tutoplast 1/135 
Wound leak repaired with suturing 1/135 
*Trabeculo-Descemet’s Window  
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FIGURES 
  
 
 
 
 
 
 
 
 
 
Figure 1. Mean intraocular pressure (IOP) and median number of drops (Drops) 
plotted against the time points. Error bars have bene excluded for clarity. *denotes 
significant difference with pre-operative values. Pre-op, pre-operative; M6, month six 
post-operative (not considered in statistical analysis); Y1, year one post-operation; 
Y2, year two post-operation; Y3, year three post-operation.   
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Figure 2. Kaplan-Meier survival plot for complete (defined as IOP≤21 mmHg with 
no medication) and qualified (defined as IOP≤21 mmHg with additional glaucoma 
medications) success.  
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Complete success 
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Figure 3. Kaplan-Meier survival plot for primary and secondary glaucoma type for 
complete success (defined as IOP≤21 mmHg with no medication, top panel) and 
qualified success (defined as IOP≤21 mmHg with additional glaucoma medications, 
bottom panel).  
 
